<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325347</url>
  </required_header>
  <id_info>
    <org_study_id>RESOLVE</org_study_id>
    <nct_id>NCT04325347</nct_id>
  </id_info>
  <brief_title>VR in Diabetic Polyneuropathy</brief_title>
  <official_title>Reducing Awakenings and Increasing Sleep Efficiency With Virtual Reality in Patients Suffering From Diabetic Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an experimental single centre study investigating the effect of VR on overall
      sleep quality and number of awakenings in patients with diabetic polyneuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sleep efficiency between experimental and control intervention.</measure>
    <time_frame>Evaluated during two time periods of two weeks.</time_frame>
    <description>Measured with actigraphy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in number of awakenings during the night between experimental and control intervention.</measure>
    <time_frame>Evaluated during two time periods of two weeks.</time_frame>
    <description>Measured with actigraphy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in subjective sleep quality between experimental and control intervention.</measure>
    <time_frame>Evaluated during two time periods of two weeks.</time_frame>
    <description>Measured with the Pittsburgh Sleep Quality Index (ranging from 0-21 with higher scores a poorer sleep quality).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain intensity reporting between experimental and control intervention.</measure>
    <time_frame>Evaluated during two time periods of two weeks.</time_frame>
    <description>Measured with Visual Analogue Scale pain diary, whereby higher scores indicate hisger pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain catastrophizing</measure>
    <time_frame>Evaluated at the end of the experimental and control intervention namely after the two-week periods.</time_frame>
    <description>Measured with the Pain Catastrophizing Scale whereby higher score are indicative for more catastrophizing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depressive symptoms</measure>
    <time_frame>Evaluated at the end of the experimental and control intervention namely after the two-week periods.</time_frame>
    <description>Measured with the Hospital Anxiety and Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status</measure>
    <time_frame>Evaluated at the end of the experimental and control intervention namely after the two-week periods.</time_frame>
    <description>Measured with the Global perceived effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any side effects of the experimental intervention</measure>
    <time_frame>Evaluated at the end of the experimental intervention namely after the two-week period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature, severity and impact of insomnia</measure>
    <time_frame>Evaluated at the end of the experimental and control intervention namely after the two-week periods.</time_frame>
    <description>Measured with the Insomnia Severity Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetic Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>Virtual reality</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virtual Reality will be provided to all participants, just before sleeping.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No specific intervention will be provided.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Virtual Reality application</intervention_name>
    <description>Virtual Reality application with a VR goggle</description>
    <arm_group_label>Virtual reality</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 70 years old

          -  Able to speak Dutch/French

          -  Continuing usual care regarding medication use 3 weeks prior and during study
             participation

          -  Diagnosis of DPN for 6 months or longer, confirmed on EMG

        Exclusion Criteria:

          -  History of seizures/epilepsia

          -  Susceptibility to motion sickness or cyber-sickness, susceptibility to claustrophobia

          -  shift workers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maarten Moens, MD PhD</last_name>
    <phone>(+32) 2 477 55 14</phone>
    <email>maarten.moens@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Goudman</last_name>
    <phone>(+32) 2 477 55 14</phone>
    <email>lisa.goudman@uzbrussel.be</email>
  </overall_contact_backup>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Moens Maarten</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

